Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Non Operating Income (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Non Operating Income for 4 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 30.16% year-over-year to $5.8 million, compared with a TTM value of $14.8 million through Dec 2025, up 10.99%, and an annual FY2025 reading of $14.8 million, up 10.99% over the prior year.
  • Non Operating Income was $5.8 million for Q4 2025 at Summit Therapeutics, up from $2.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $16.1 million in Q4 2023 and bottomed at -$5.2 million in Q1 2023.
  • Average Non Operating Income over 4 years is $3.5 million, with a median of $2.7 million recorded in 2025.
  • Peak annual rise in Non Operating Income hit 689.95% in 2024, while the deepest fall reached 72.55% in 2024.
  • Year by year, Non Operating Income stood at $5.5 million in 2022, then skyrocketed by 194.35% to $16.1 million in 2023, then tumbled by 72.55% to $4.4 million in 2024, then soared by 30.16% to $5.8 million in 2025.
  • Business Quant data shows Non Operating Income for SMMT at $5.8 million in Q4 2025, $2.4 million in Q3 2025, and $2.7 million in Q2 2025.